Auro Nair

Dr. Auro Nair

Former Executive Vice President of The Jackson Laboratory (JAX)

Former President, JAX® Mice, Clinical and Research Services (JMCRS)

Auro Nair has over 30 years of leadership experience in the biopharma, life sciences, and biomedical research space.  He most recently served, until September 2022, as Executive Vice President of The Jackson Laboratory (JAX) and President, JAX® Mice, Clinical and Research Services (JMCRS).  Auro joined JAX in 2007 as associate general manager and, with a strong focus on innovation and customer experience, led the expansion of JMCRS into an enterprise that is seven times larger than it was when he joined.  This growth included the establishment of new sites in Sacramento, California and Ellsworth, Maine, the development and launch of leading-edge preclinical services and humanized mouse platforms enabling biopharma drug development, and the creation of clinical services.  Following multiple promotions, Auro was named the first President of JMCRS in 2017 and was also promoted to Executive Vice President of The Jackson Laboratory in 2018.  Auro has driven the international expansion of JAX, most recently through the establishment of JAX’s first joint venture company in China in November 2020 and the acquisition of Charles River Japan in October 2021.  He served as the chairman of the board for both of these international organizations.  In recognition of his leadership impact, Auro was named as a co-honoree of The Robert Alvine Family Endowed Chair that was established by Robert Alvine, chair emeritus of the JAX Board of Trustees.

Prior to JAX, Auro had served as Vice President for worldwide marketing and North American sales with Caliper Life Sciences (now part of PerkinElmer) where he led the launch of multiple new products and services.  He began his career in commercial leadership upon joining Zymark, Caliper’s predecessor organization in 1997 as director of business development.  From 1990 to 1997 Auro served in positions of increasing scientific and operational management responsibility at GlaxoSmithKline’s FDA-approved site in Singapore, ultimately managing all Quality Compliance and Analytical Services.

Auro is a graduate in chemistry of the University of Science, Penang, Malaysia; holds a Ph.D. in chemistry from the University of Oklahoma, Norman; and has an executive MBA from Suffolk University in Boston, Massachusetts.